Healthcare and life-sciences growth equity fund research profile
InvAscent India Life Sciences Fund IV is a healthcare-focused growth-equity vehicle managed by Invascent. IFC identifies a US$325 million combined target with the domestic fund, a US$10–50 million average company ticket and five Fund IV investees; InvAscent’s own releases add direct vehicle attribution for Apex Hospitals and SRV Hospitals.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
InvAscent India Life Sciences Fund IV uses a healthcare and life-sciences growth equity approach across Pharma, healthcare delivery, medtech, animal health.
Current evidence
InvAscent announced on 30 September 2025 that ILSF IV invested INR 230 crore in Apex Hospitals. Earlier ILSF IV announcements covered SRV Hospitals in April 2025, Geri Care in January 2025, Maiva Pharma in May 2024 and ABI Health Technologies in December 2023.
Strategy
Healthcare and life-sciences growth equity
Sector focus
Pharma, healthcare delivery, medtech, animal health
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
InvAscent announced on 30 September 2025 that ILSF IV invested INR 230 crore in Apex Hospitals. Earlier ILSF IV announcements covered SRV Hospitals in April 2025, Geri Care in January 2025, Maiva Pharma in May 2024 and ABI Health Technologies in December 2023.
Investor questions
InvAscent India Life Sciences Fund IV is covered in Rupeia's private equity research universe. The current public record describes the strategy as Healthcare and life-sciences growth equity, with a sector focus of Pharma, healthcare delivery, medtech, animal health. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to InvAscent India Life Sciences Fund IV in the reviewed public sources: ABI Health Technologies Private Limited; Maiva Pharma Private Limited; Geri Care Health Services; SRV Hospitals; Apex Hospitals Private Limited; Fleming Laboratories; Map Care. It does not represent a complete current portfolio unless the manager has published one.
The manager disclosed 2023–2025 investments in ABI Health, Maiva Pharma, Geri Care, SRV Hospitals and Apex Hospitals. Fund IV-specific realised returns, DPI, TVPI and final exit history are not publicly disclosed. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: US$325 million combined target for India Life Sciences Fund IV and the domestic fund, with IFC investment of up to US$25 million capped at 19.99% of commitments. Fund IV final close is not publicly disclosed.. Public terms or access information: Category II growth-equity fund focused on small and mid-market Indian healthcare and life-sciences companies; IFC describes an average ticket of US$10–50 million across 12–15 companies. Fees, carry, hurdle, fund tenor and reserve policy are not publicly disclosed.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Hariharnath (Hari) Buggana (Chairman and Managing Director); Nithya Govind (Managing Director); Sumit Gupta (Managing Director); Dr. Jeevak Gupta (Director – Investments); Anil Jagirdar (Director / Compliance Officer). Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: The IFC disclosure and manager announcements establish the vehicle and named investments, but final close, exact fund-level fees/carry, realised returns and a complete current portfolio schedule are not publicly disclosed. The record is limited to positions directly attributed to ILSF IV or identified in the IFC Fund IV portfolio disclosure..
2025-09-30: InvAscent announced on 30 September 2025 that ILSF IV invested INR 230 crore in Apex Hospitals. Earlier ILSF IV announcements covered SRV Hospitals in April 2025, Geri Care in January 2025, Maiva Pharma in May 2024 and ABI Health Technologies in December 2023.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.